OPRM1 and prostate cancer: Concurrent translational investigation has revealed that increased expression of μ-opioid receptors (MOR) in non-small cell lung cancer [3], prostate cancer [4], gastric cancer [5] and melanoma [6, 7] is associated with greater degree of metastasis [8].